Maven Securities’s Aligos Therapeutics ALGS Stock Holding History

Maven Securities’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-729	Closed	-$364K	–	1030
2021 Q1	$364K	Buy	+729	New	+$485K	0.02%	763

Other funds holding ALGS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maven Securities's ALGS Position: Q2 2021 in Review

Maven Securities sold out of Aligos Therapeutics (ALGS) in Q2 2021, closing a stake of 729 shares — an estimated $364K sold.

Maven Securities first reported a position in ALGS in Q1 2021 and held it in 1 quarter. The position peaked at $364K in Q1 2021. 57 funds tracked by Wall St. Rank hold ALGS as of Q2 2021.

Maven Securities reported no remaining Aligos Therapeutics position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 729 Aligos Therapeutics shares in Q2 2021, an estimated $364K.
Maven Securities first reported a position in Aligos Therapeutics in Q1 2021 and held it in 1 quarter.
Maven Securities's Aligos Therapeutics position peaked at $364K in Q1 2021.
57 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.